Unlocking the Transformative Power of Meitheal Xentria's Platform

... Meitheal's General Counsel & Corporate Secretary since its inception in 2017. In addition, Victoria is the Corporate Secretary of Xentria, Inc. a biotech ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... 事件：公司公告，子公司香港健友及其控股子公司Meitheal拟与Xentria签署《许可协议》，Xentria授予健友在许可区域开发和商业化XTMAB的独占许可，并向 ... Under the terms of the agreement, Meitheal Pharmaceuticals gains exclusive rights to commercialize XTMAB-16 in North America and Xentria remains ... Targeted Delivery of ASO Gapmers to Muscle for the Treatment of Myotonic Dystrophy Type 1 · Xentria and Meitheal Collaborate on Breakthrough Lung ... 格隆汇6月27日丨健友股份(603707.SH)公布，公司全资子公司香港健友及香港健友控股子公司Meitheal拟与Xentria签署《许可协议》，Xentria授予被许可方在 ... Xentria, Meitheal Pharma enter licensing agreement ... Chicago-based biotech Xentria announced this week that it has signed a multi-year licensing ... Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America. Endpoints News - Jun 27, 2023. Companies are right to embrace ... ... Meitheal Pharmaceuticals, Inc.（以下简称“Meitheal”“被许可方”）拟与Xentria，Inc（以下简称“Xentria”） 签署《许可、开发与商业化协议》（以下简称 ... Jul 5, 2023 Meitheal, Xentria to market XTMAB-16 for pulmonary sarcoidosis |... Publisher: Sarcoidosis News. News Summary: Meitheal acquires the sole rights to ...